(19)
(11) EP 1 001 813 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.02.2014 Bulletin 2014/07

(45) Mention of the grant of the patent:
02.05.2003 Bulletin 2003/18

(21) Application number: 98930793.9

(22) Date of filing: 02.06.1998
(51) International Patent Classification (IPC): 
A61K 47/40(2006.01)
 A61K 31/505(2006.01)
(86) International application number:
PCT/EP1998/003477
(87) International publication number:
WO 1998/058677 (30.12.1998 Gazette 1998/52)

(54)

PHARMACEUTICAL FORMULATIONS CONTAINING VORICONAZOLE

VORICONAZOL-ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN

FORMULATIONS PHARMACEUTIQUES CONTENANT DU VORICONAZOLE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 21.06.1997 GB 9713149

(43) Date of publication of application:
24.05.2000 Bulletin 2000/21

(73) Proprietors:
  • Pfizer Limited
    Sandwich, Kent CT13 9NJ (GB)
    Designated Contracting States:
    GB 
  • Pfizer Inc.
    New York, NY 10017 (US)
    Designated Contracting States:
    AT BE CH CY DE DK ES FI FR GR IE IT LI LU NL PT SE 

(72) Inventor:
  • HARDING, Valerie, Denise
    Sandwich, Kent CT13 9NJ (GB)

(74) Representative: Hayles, James Richard 
Pfizer
ATTENTION: ADDRESS INACTIVE - USE ASS-NR - CDR
ATTENTION: ADDRESS INACTIVE - USE ASS-NR - CDR (FR)


(56) References cited: : 
EP-A- 0 357 241
WO-A-91/11172
WO-A-97/01552
 EP-A- 0 440 372
WO-A-94/02518
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).